共查询到20条相似文献,搜索用时 31 毫秒
1.
Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis 总被引:10,自引:0,他引:10
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Song CH Kim HJ Park JK Lim JH Kim UO Kim JS Paik TH Kim KJ Suhr JW Jo EK 《Infection and immunity》2000,68(8):4477-4484
The secreted 30-kDa antigen (Ag) of Mycobacterium tuberculosis directly stimulates Th1-type protective cytokine responses in healthy tuberculin reactors but not in patients with active tuberculosis (TB). To examine the cytokine profiles attributable to Th1 suppression associated with active TB, interleukin-12 (IL-12), IL-18, and IL-10 production in response to a 30- or 32-kDa Ag in 16 patients with active pulmonary TB and 24 healthy controls was investigated by enzyme-linked immunosorbent assay. In TB patients, production of IL-12 p40, as well as gamma interferon (IFN-gamma), by 30- or 32-kDa Ag-stimulated peripheral blood mononuclear cells (PBMC) was significantly decreased compared with that in healthy tuberculin reactors. There were no significant differences in IL-18 production between patients and controls early during stimulation (16 h). However, PBMC from patients showed significantly enhanced IL-18 proteins after 96 h of stimulation. Similarly, higher IL-10 production was observed in the TB patients than in healthy tuberculin reactors. After 2 months of anti-TB therapy, the mean IFN-gamma and IL-12 p40 production and the mean blastogenic responses were significantly increased in PBMC in the 10 TB patients who were followed up. Our findings provide evidence that depressed IL-12 in response to the 30- or 32-kDa Ag is involved in the immunopathogenesis of human active pulmonary TB. 相似文献
2.
3.
Differential Live Mycobacterium tuberculosis-, M. bovis BCG-, Recombinant ESAT6-, and Culture Filtrate Protein 10-Induced Immunity in Tuberculosis
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Zahra Hasan Bushra Jamil Mussarat Ashraf Muniba Islam Maqboola Dojki Muhammad Irfan Rabia Hussain 《Clinical and Vaccine Immunology : CVI》2009,16(7):991-998
The high prevalence of Mycobacterium tuberculosis makes it imperative that immune responses to evaluate could be predictive of infection. We investigated live Mycobacterium- and recombinant antigen-induced cytokine and chemokine responses in patients with active tuberculosis (TB) compared with those of healthy controls from an area where TB is endemic (ECs). M. tuberculosis-, M. bovis BCG-, ESAT6-, and culture filtrate protein 10 (CFP10)-induced responses were determined in peripheral blood mononuclear cells from patients with pulmonary TB (n = 38) and ECs (n = 39). The levels of the cytokines gamma interferon (IFN-γ) and interleukin-10 (IL-10) and the chemokines CCL2, CCL3, and CXCL9 were measured. The levels of M. tuberculosis- and BCG-induced IFN-γ secretion were significantly reduced (P = 0.002 and P < 0.01, respectively), while the amount of IL-10 induced by both virulent (P < 0.01) and avirulent (P = 0.002) mycobacteria was increased in patients with TB. The ESAT6-induced IFN-γ responses were increased in the patients with TB (P = 0.013) compared with those in the EC group. When tuberculin skin test (TST)-negative (TST−; induration, <10 mm) and TST-positive (TST+) donors were studied separately, both TST− and TST+ individuals showed increased IFN-γ responses to M. tuberculosis compared with the responses of the patients with TB (P = 0.037 and P = 0.006, respectively). However, only TST+ ECs showed reduced IFN-γ responses to ESAT6 (P = 0.008) compared with the responses of the patients with TB. The levels of M. tuberculosis-induced CCL2 (P = 0.006) and CXCL9 (P = 0.017) were greater in the patients with TB. The levels of CCL3 secretion in response to Mycobacterium and antigen stimulation were comparable between the two groups. While the levels of ESAT6-induced chemokines did not differ between the patients with TB and the ECs, the levels of CFP10-induced CCL2 (P = 0.01) and CXCL9 (P = 0.001) were increased in the patients. These data indicate differential host IFN-γ, CXCL9, and CCL2 responses to live mycobacteria and mycobacterial antigens and have implications for the identification of potential biomarkers of infection which could be used for the diagnosis of TB.Tuberculosis (TB) remains an important cause of mortality and morbidity worldwide, causing 2 million deaths annually. Vaccination with Mycobacterium bovis BCG provides protection mostly during childhood and primarily against the extrapulmonary forms of the disease (28, 45, 49). It is important to identify immune markers that may be reflective of natural infection in the host and that may therefore be useful in predicting the outcome of the disease.Host immune responses determine the outcome of M. tuberculosis infection. The balance between the key T-cell cytokines gamma interferon (IFN-γ) and interleukin-10 (IL-10), which are produced by macrophages and subsets of T cells, is key to the maintenance of effector responses against the mycobacterium (13, 34). This is further reflected by the relationship between IFN-γ and IL-10, which differs according to the severity of the disease, especially in patients with extrapulmonary M. tuberculosis infections (24).The formation and maintenance of granulomas are essential for the control of mycobacterial infections. Tumor necrosis factor alpha (TNF-α) is critical to an effective response against M. tuberculosis and for efficient granuloma formation (38). TNF−/− mice show increased pathology and a more rapid progression of disease during infection with M. tuberculosis (6).IFN-γ- and macrophage-induced TNF-α activates and regulates the C-C chemokines CCL2, CCL3, CCL4, and CCL5 and the C-X-C chemokines CXCL8, CXCL9, CXCL10, and CXCL11 (2) (42). These chemokines have been shown to play an important role in the recruitment and activation of leukocytes at the site of granuloma formation.CCL2 is the most potent activator of monocytes and is essential for recruitment and migration to the lung. Studies with CCL2−/− mice have investigated the pathology of M. tuberculosis infection (26) and have shown that CCCR2−/− mice exhibit faulty granuloma formation and increased susceptibility to disease caused by M. tuberculosis (44). IFN-γ-activated chemokines, such as CXCL9 and CXCL10, are induced by M. tuberculosis antigens (1, 40).The circulating levels of cytokines such as IFN-γ, IL-10, transforming growth factor-β, and chemokine CXCL9 are found to be raised in patients with TB (17, 33). Patients with pulmonary TB also display increases in the level of monocyte-activating chemokine CCL2 (20). An increase in the CCL2 level is associated with monocyte migration to the lung and the reduced progression of disease (26, 43). Recent studies have identified molecular mechanisms which are deficient in patients with pulmonary TB. These include reduced IFN-γ responses at the disease site (21) and a reduced monocyte maturation ability concomitant with a reduction in the levels of markers of antigen presentation, such as major histocompatibility complex class II expression (36). In addition, it has been shown that granulomas differ in cavitary and noncavitary TB (48). This further emphasizes the need to understand the pattern of recognition of mycobacterial antigens in different forms of TB and in transitions from latent to active infection.Six-kilodalton early secreted antigenic target 6 (ESAT6) and culture filtrate protein 10 (CFP10) are both encoded by region of difference 1 (RD1), which is present in M. tuberculosis and M. bovis but which is absent from M. bovis BCG and most environmental mycobacteria (8, 16). ESAT6 is an immunodominant T-cell-stimulatory antigen and is recognized by specific IFN-γ-secreting T cells that are present in greater numbers in patients with active disease than in those who are uninfected (37, 47). The importance of these recombinant antigens is in their immune recognition by T cells specific to infected individuals. They are a primary component of new diagnostic assays and are meant to detect latent infections in individuals because of their lack of cross-reactivity with M. bovis BCG, which is used for vaccination (27). Commercial tests that use IFN-γ-release assays are increasingly available as diagnostic and predictive tests for newer-generation vaccines. ESAT6- and CFP10-induced IFN-γ responses have been shown to be useful in discriminating infected individuals from healthy controls (1, 9, 46). Demissie et al. have shown that immune responses to ESAT6 are more likely to be associated with active infection and that a dormancy-related antigen (HspX or α-crystallin) might be a better marker of latency in patients with TB, while cross-reactive antigens, such as the antigen 85A complex, do not distinguish between active and latent TB (11).Antigen recognition and binding to cell surface receptors result in cytokine activation and intracellular signaling cascades within the host cell (14, 39). Virulent M. tuberculosis organisms are efficient at evading macrophage host defenses, such as phagolysosome fusion; downregulation of the activation of proinflammatory cytokines, such as TNF-α; inhibition of antigen presentation; and also host apoptotic responses (19, 25). In contrast, avirulent mycobacteria, such as the M. bovis BCG strain, are processed along the endosomal pathway, activating stronger responses of proinflammatory cytokines, such as TNF-α, IL-2, and IL-6, than the responses activated by virulent mycobacteria (7). In addition, the uptake and processing of live and dead mycobacteria differ in host cells (18). Therefore, although both mycobacteria and mycobacterial antigens can stimulate host immunity, it is likely that their immunogenicities may differ due to processing and presentation of antigens.There is as yet a limited understanding of how host cell responses differ when the host is challenged with live mycobacteria as opposed to mycobacterial antigens. We investigated the differential cytokine responses to live mycobacteria (virulent M. tuberculosis and avirulent M. bovis BCG strains) and compared them with those to the M. tuberculosis antigens ESAT6 and CFP10. BCG vaccination is widespread in Pakistan and since 1981 has routinely been administered at birth through the Expanded Program for Immunization (51). Therefore, the levels of cytokine and chemokine secretion by peripheral blood mononuclear cells (PBMCs) in response to different stimuli were analyzed in patients with pulmonary TB and were compared with those in healthy vaccinated controls from areas where TB is endemic (ECs). Our results highlight the variability of host responses to mycobacteria and mycobacterial antigens. 相似文献
4.
Eui-Ryoung Han Inseon S. Choi Han-Gyu Choi Hwa-Jung Kim 《Allergy, asthma & immunology research》2012,4(4):214-221
Purpose
Live/killed mycobacteria and culture supernatants can suppress asthmatic reactions. This study investigated whether mycobacterial secretory proteins have therapeutic effects on asthma.Methods
Mycobacterium bovis bacille Calmette-Guérin (BCG; 2×105 CFUs) and mycobacterial secretory proteins (Ag85 complex, 38-kDa protein or MPB70; 4 or 20 µg) were administered intraperitoneally to female BALB/c mice with established airway hyperresponsiveness. One week after treatment, the mice underwent a methacholine challenge test, and then inflammatory cell numbers in bronchoalveolar lavage fluid (BAL) and around bronchi (<500 µm), and cytokine levels in splenocyte supernatants, were assessed.Results
BCG and all of the tested secretory proteins significantly improved airway sensitivity compared to baseline values (P<0.05). The secretory protein Ag85 complex significantly suppressed airway reactivity also (P<0.05), while 38-kDa protein significantly suppressed reactivity and maximal narrowing (P<0.05). The number of eosinophils in BAL and around bronchi, and the goblet cell proportion, were also significantly reduced in mice in both the BCG and secretory protein groups compared to the asthma control group. IFN-γ/IL-5 ratios were significantly higher in mice treated with BCG, 4 µg MPB70 or 4 µg 38-kDa protein than in asthma control mice (P<0.05), and were negatively associated with airway hyperresponsiveness, peribronchial eosinophil numbers and goblet cell proportion (all P<0.05). IL-17A was positively correlated with IL-5 (r=0.379, P<0.001), maximal airway narrowing, peribronchial eosinophil numbers and goblet cell proportion (all P<0.05).Conclusions
Secretory proteins from BCG and M. tuberculosis and live BCG were effective against established asthma, their effects being accompanied by increased IFN-γ/IL-5 ratios. Thus, allergic asthma could be effectively treated with mycobacterial secretory proteins. 相似文献5.
6.
Gamma Interferon Responses Induced by a Panel of Recombinant and Purified Mycobacterial Antigens in Healthy, Non-Mycobacterium bovis BCG-Vaccinated Malawian Young Adults
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Gillian F. Black Rosemary E. Weir Steven D. Chaguluka David Warndorff Amelia C. Crampin Lorren Mwaungulu Lifted Sichali Sian Floyd Lyn Bliss Elizabeth Jarman Linda Donovan Peter Andersen Warwick Britton Glyn Hewinson Kris Huygen Jens Paulsen Mahavir Singh Ross Prestidge Paul E. M. Fine Hazel M. Dockrell 《Clinical and Vaccine Immunology : CVI》2003,10(4):602-611
We have previously shown that young adults living in a rural area of northern Malawi showed greater gamma interferon (IFN-γ) responses to purified protein derivatives (PPD) prepared from environmental mycobacteria than to PPD from Mycobacterium tuberculosis. In order to define the mycobacterial species to which individuals living in a rural African population have been exposed and sensitized, we tested T-cell recognition of recombinant and purified antigens from M. tuberculosis (38 kDa, MPT64, and ESAT-6), M. bovis (MPB70), M. bovis BCG (Ag85), and M. leprae (65 kDa, 35 kDa, and 18 kDa) in >600 non-M. bovis BCG-vaccinated young adults in the Karonga District of northern Malawi. IFN-γ was measured by enzyme-linked immunosorbent assay (ELISA) in day 6 supernatants of diluted whole-blood cultures. The recombinant M. leprae 35-kDa and 18-kDa and purified native M. bovis BCG Ag85 antigens induced the highest percentages of responders, though both leprosy and bovine tuberculosis are now rare in this population. The M. tuberculosis antigens ESAT-6 and MPT64 and the M. bovis antigen MPB70 induced the lowest percentages of responders. One of the subjects subsequently developed extrapulmonary tuberculosis; this individual had a 15-mm-diameter reaction to the Mantoux test and responded to M. tuberculosis PPD, Ag85, MPT64, and ESAT-6 but not to any of the leprosy antigens. We conclude that in this rural African population, exposure to M. tuberculosis or M. bovis is much less frequent than exposure to environmental mycobacteria such as M. avium, which have antigens homologous to the M. leprae 35-kDa and 18-kDa antigens. M. tuberculosis ESAT-6 showed the strongest association with the size of the Mantoux skin test induration, suggesting that among the three M. tuberculosis antigens tested it provided the best indication of exposure to, or infection with, M. tuberculosis. 相似文献
7.
Recombinant Mycobacterium bovis BCG Expressing the Chimeric Protein of Antigen 85B and ESAT-6 Enhances the Th1 Cell-Mediated Response
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ying Xu Wei Liu Hongbo Shen Jingran Yan Di Qu Honghai Wang 《Clinical and Vaccine Immunology : CVI》2009,16(8):1121-1126
The chimeric protein that relies on the T-cell epitopes of antigen 85B (Ag85B) and the 6-kDa early secreted antigen target (ESAT-6) has been demonstrated to augment the Th1 immune response. In this study, we developed a recombinant Mycobacterium bovis BCG (rBCG) strain that secretes the chimeric protein of Ag85B and ESAT-6 (rBCG-AN-E-AC). Immunization with this rBCG strain induced stronger antigen-specific gamma interferon (IFN-γ) activities, as determined by an enzyme-linked immunospot assay, and higher levels of antigen-specific CD4+ and CD8+ T-cell responses than those in the control groups immunized with either rBCG expressing the Ag85B-ESAT-6 fusion protein (rBCG-A-E) or BCG. Likewise, rBCG-AN-E-AC significantly increased the level of production of the major Th1 cytokines IFN-γ and tumor necrosis factor alpha in splenocyte cultures to levels comparable to those elicited by control BCG. Moreover, the antigen-specific immunoglobulin 2c (IgG2c)/IgG1 ratio for mice immunized with rBCG-AN-E-AC was also much higher than the ratios for the other immunized groups. Together, these results indicate that this rBCG-AN-E-AC strain enhances the Th1 cell-mediated response and may serve as a potential vaccine against M. tuberculosis.Mycobacterium bovis bacillus Calmette Guérin (BCG) is the only vaccine against tuberculosis (TB) currently available and exhibits various levels of efficacy for the prevention of pulmonary TB (range, 0 to 80%) in different trials (9). BCG has a protective effect in children, particularly against tuberculous meningitis; however, it does not satisfactorily prevent the development of pulmonary TB in adults and fails to protect individuals against reinfection (1). Given the rate of mortality from TB worldwide, with more 8 million new cases and 2 million deaths occurring annually (2), newer strategies need to be implemented to improve BCG or vaccines more effective than BCG urgently need to be developed.One approach that might be used to increase the efficacy of BCG could be to construct a recombinant BCG (rBCG) which either overexpresses immunogenic antigens or modulates the ensuing immune response (8). rBCG vaccines are attractive because of the widespread experience with their use, the known immunogenicity associated with protection against the worst forms of the disease in children, and the safety profiles of standard BCG strains (13). Two rBCG vaccines have been entered into clinical trials. This includes rBCG30, which expresses the antigen 85B (Ag85B) protein, and ΔureC hly-positive rBCG, which expresses listeriolysin and which is urease deficient (12, 15). It is hoped that these vaccines will provide a strong and perhaps longer-lasting immune response than that achieved with the conventional BCG vaccine.The most effective defined-antigen TB vaccines will likely require the induction of both cell-mediated and humoral immune responses. Ag85B and the 6-kDa early secreted antigen target (ESAT-6) have been identified as two of the most promising vaccine candidates which are strongly recognized by T lymphocytes (3, 19). In a previous study, we relied on the T-cell epitopes of Ag85B and ESAT-6 to design a chimeric protein by inserting ESAT-6 into Ag85B from amino acids 167 to 182 and demonstrated that this recombination of Ag85B and ESAT-6 could improve the immunogenicity and enhance the T-helper type 1 (Th1) cell-mediated immune response (27). This finding prompted us to explore further the efficacy of rBCG overexpressing this chimeric protein. In this study, we constructed rBCG expressing chimeric protein Ag85BN-ESAT-6-Ag85BC (rBCG-AN-E-AC) and further compared the immune response to that protein with that to rBCG expressing the Ag85B-ESAT-6 fusion protein (rBCG-A-E) and BCG. 相似文献
8.
Xueqiong Wu Yourong Yang Junxian Zhang Bangying Li Yan Liang Chuiying Zhang Mei Dong Hongbing Cheng Jufang He 《Clinical and Vaccine Immunology : CVI》2010,17(3):372-375
The diagnosis of smear-negative and culture-negative patients with active tuberculosis (TB) is challenging. The detection of Mycobacterium tuberculosis-specific antibodies in human sera has been an important diagnostic aid. However, detection of antibody responses to a single antigen usually has a low sensitivity for diagnosis of TB. In this study, humoral immune responses against recombinant M. tuberculosis 38-kDa, MTB48, and CFP-10/ESAT-6 (culture filtrate protein 10/6-kDa early secreted antigen target of M. tuberculosis) antigens in 250 Chinese TB patients and 260 healthy subjects were evaluated by an enzyme-linked immunosorbent assay (ELISA). The levels of antibodies against those antigens in TB patients, even in bacterium-negative ones, were significantly higher than those in healthy subjects (P < 0.001). The serodiagnostic sensitivities to detect antibodies against individual antigens, i.e., recombinant M. tuberculosis 38-kDa, MTB48, and CFP-10/ESAT-6 antigens, in TB patients were 73.6%, 73.2%, and 60.4%, respectively, with specificities of 85.4%, 77.7%, and 73.8%, respectively. Importantly, the sensitivity to positively detect humoral responses to one of the antigens increased further. Our data suggest that the humoral immune responses to M. tuberculosis antigens in TB patients are heterogeneous. The 38-kDa, MTB48, and CFP-10/ESAT-6 antigens can be used as the cocktail antigens in the serodiagnosis of active TB, especially for smear- or culture-negative TB cases.The control of tuberculosis (TB) remains challenging in China (18). Currently, the diagnosis of active TB mainly relies on clinical symptoms, radiologic findings, and the detection of Mycobacterium tuberculosis in clinical samples using smear staining and mycobacterial culture. However, the diagnosis of TB in smear- and culture-negative TB patients is difficult. The detection of M. tuberculosis-specific antibodies in human sera has been an important aid in diagnosis of TB. Notably, several antigens have been demonstrated to have merit in TB diagnosis, including the 38-kDa protein, which is commonly used in serodiagnostic tests (4, 5, 8, 13, 19, 22, 23). Previous studies suggest that the antibody responses to M. tuberculosis antigens are heterogeneous among individuals (17) so that the detection of antibodies against a single antigen usually has a low sensitivity for diagnosis of TB, especially for bacterium-negative cases. Therefore, it may be valuable to evaluate antibodies against the 38-kDa antigen and other major antigens for the diagnosis of active TB (14, 15).Notably, the MTB48, CFP-10 (culture filtrate protein 10), and ESAT-6 (6-kDa early secreted antigen target of M. tuberculosis) genes are conserved in M. tuberculosis and Mycobacterium bovis isolates but partially deleted or absent in M. bovis BCG as well as in most nontuberculous mycobacteria (NTM) (1-3, 10, 16). Importantly, the proteins encoded by these genes are immunogenic (7, 9, 12, 16). In this study, we cloned the 38-kDa, MTB48, CFP-10, and ESAT-6 genes and generated recombinant 38-kDa, MTB48, and CFP-10/ESAT-6 fusion proteins in Escherichia coli. Subsequently, we developed an enzyme-linked immunosorbent assay (ELISA) for the characterization of serum antibodies against 38-kDa, MTB48, and CFP-10/ESAT-6 antigens in a population of 250 active TB patients and 260 healthy subjects. We found that characterization of antibodies against multiple M. tuberculosis antigens were valuable for the diagnosis of active TB. 相似文献
9.
Helen A. Fletcher Rachel Tanner Robert S. Wallis Joel Meyer Zita-Rose Manjaly Stephanie Harris Iman Satti Richard F. Silver Dan Hoft Beate Kampmann K. Barry Walker Hazel M. Dockrell Uli Fruth Lew Barker Michael J. Brennan Helen McShane 《Clinical and Vaccine Immunology : CVI》2013,20(11):1683-1689
Despite the widespread use of the Mycobacterium bovis BCG vaccine, there are more than 9 million new cases of tuberculosis (TB) every year, and there is an urgent need for better TB vaccines. TB vaccine candidates are selected for evaluation based in part on the detection of an antigen-specific gamma interferon (IFN-γ) response. The measurement of mycobacterial growth in blood specimens obtained from subjects immunized with investigational TB vaccines may be a better in vitro correlate of in vivo vaccine efficacy. We performed a clinical study with 30 United Kingdom adults who were followed for 6 months to evaluate the abilities of both a whole-blood- and a novel peripheral blood mononuclear cell (PBMC)-based mycobacterial growth inhibition assay to measure a response to primary vaccination and revaccination with BCG. Using cryopreserved PBMCs, we observed a significant improvement in mycobacterial growth inhibition following primary vaccination but no improvement in growth inhibition following revaccination with BCG (P < 0.05). Mycobacterial growth inhibition following primary BCG vaccination was not correlated with purified protein derivative (PPD) antigen-specific IFN-γ enzyme-linked immunospot (ELISPOT) responses. We demonstrate that a mycobacterial growth inhibition assay can detect improved capacity to control growth following primary immunization, but not revaccination, with BCG. This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in vaccine responses by comparing both primary and secondary BCG vaccinations, suggesting that in vitro growth inhibition assays may serve as better surrogates of clinical efficacy than the assays currently used for the assessment of candidate TB vaccines. 相似文献
10.
Natalie A. Parlane Katrin Grage Jun Mifune Randall J. Basaraba D. Neil Wedlock Bernd H. A. Rehm Bryce M. Buddle 《Clinical and Vaccine Immunology : CVI》2012,19(1):37-44
New improved vaccines are needed for control of both bovine and human tuberculosis. Tuberculosis protein vaccines have advantages with regard to safety and ease of manufacture, but efficacy against tuberculosis has been difficult to achieve. Protective cellular immune responses can be preferentially induced when antigens are displayed on small particles. In this study, Escherichia coli and Lactococcus lactis were engineered to produce spherical polyhydroxybutyrate (PHB) inclusions which displayed a fusion protein of Mycobacterium tuberculosis, antigen 85A (Ag85A)–early secreted antigenic target 6-kDa protein (ESAT-6). L. lactis was chosen as a possible production host due its extensive use in the food industry and reduced risk of lipopolysaccharide contamination. Mice were vaccinated with PHB bead vaccines with or without displaying Ag85A–ESAT-6, recombinant Ag85A–ESAT-6, or M. bovis BCG. Separate groups of mice were used to measure immune responses and assess protection against an aerosol M. bovis challenge. Increased amounts of antigen-specific gamma interferon, interleukin-17A (IL-17A), IL-6, and tumor necrosis factor alpha were produced from splenocytes postvaccination, but no or minimal IL-4, IL-5, or IL-10 was produced, indicating Th1- and Th17-biased T cell responses. Decreased lung bacterial counts and less extensive foci of inflammation were observed in lungs of mice receiving BCG or PHB bead vaccines displaying Ag85A–ESAT-6 produced in either E. coli or L. lactis compared to those observed in the lungs of phosphate-buffered saline-treated control mice. No differences between those receiving wild-type PHB beads and those receiving recombinant Ag85A–ESAT-6 were observed. This versatile particulate vaccine delivery system incorporates a relatively simple production process using safe bacteria, and the results show that it is an effective delivery system for a tuberculosis protein vaccine. 相似文献
11.
《Mucosal immunology》2019,12(3):805-815
Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB), is the leading killer due to an infectious organism. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only vaccine approved against TB, however, its efficacy against pulmonary TB is poor. While BCG is currently inoculated intradermally, the natural route of M.tb infection is through the lung. Excessive lung pathology caused by pulmonary inoculation of BCG has prevented the use of this immunization route. Here, we show that selective chemical treatment of BCG with petroleum ether removes inflammatory lipids from the bacterial surface while keeping BCG viable. Pulmonary vaccination using this modified BCG attenuated inflammatory responses, prevented immunopathology of the lung, and significantly increased protection against M.tb infection in mice. We further directly linked IL-17A as the responsible contributor of improved immunity against M.tb infection. These results provide evidence that selective removal of cytotoxic lipids from the BCG surface attenuates inflammation and offers a safer and superior vaccine against TB causing less damage post-infectious challenge with M.tb. 相似文献
12.
Bryce M. Buddle R. Glyn Hewinson H. Martin Vordermeier D. Neil Wedlock 《Clinical and Vaccine Immunology : CVI》2013,20(10):1559-1562
Vaccination of cattle with a commercial human tuberculosis (TB) vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG) Danish, at a dose equivalent to 5 human doses of BCG has protected these animals against TB in field and experimental trials. There is interest in determining whether a 10-fold-lower dose could still protect cattle but not induce a tuberculin intradermal test response. Two groups of calves (n = 9/group) were vaccinated subcutaneously with a lyophilized BCG Danish vaccine containing either 0.5 (1 × 105 to 4 × 105 CFU) or 5 (1 × 106 to 4 × 106 CFU) human doses of BCG Danish, with an additional group of 10 calves serving as nonvaccinated controls. Fifteen weeks after vaccination, these animals were challenged intratracheally with 5 × 103 CFU of virulent M. bovis and another 15 weeks later were slaughtered and examined for the presence of tuberculous lesions. Vaccination of the calves with either 0.5 or 5 equivalent human doses of BCG Danish induced similar levels of protection against challenge with M. bovis, with both groups showing significant reductions in the pathological and microbiological parameters compared to those for the the control group (P < 0.05). Vaccination with either of the two BCG doses induced similar numbers of animals responding to the tuberculin intradermal test at 11 weeks postvaccination. Vaccination with a 0.5 equivalent human dose of a commercial lyophilized BCG vaccine can protect cattle against challenge with M. bovis. 相似文献
13.
14.
Gareth J. Jones R. Glyn Hewinson H. Martin Vordermeier 《Clinical and Vaccine Immunology : CVI》2010,17(9):1344-1348
To date, the most promising vaccination strategies for the control of bovine tuberculosis (TB) focus on improving the efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG). However, vaccination with BCG results in sensitization of animals to bovine tuberculin and compromises tests currently used for diagnosis of bovine TB infection. Thus, the development of specific diagnostic reagents capable of discriminating between infected and uninfected vaccinated animals (DIVA) is of high priority. To test the hypothesis that M. bovis-secreted proteins are likely to contain immunogenic antigens that can be used to increase the specificity of diagnostic tests, we screened 379 pools of overlapping peptides representing 119 antigens for their ability to stimulate a gamma inferferon (IFN-γ) response in vitro using whole blood from both TB reactor and BCG-vaccinated animals. Peptide pools representing antigens Rv3020c and Rv2346c induced responses in 61% and 57% of the TB reactor animals, respectively, without inducing responses in any BCG-vaccinated animal studied. Furthermore, individual peptides contained within pools recognized by BCG vaccinates were identified that were specific and induced IFN-γ responses in TB reactor animals. From these results, we constructed a cocktail of nine peptides representing multiple antigen targets that was recognized by 54% of TB reactor animals but also failed to induce responses in any BCG-vaccinated animal studied. In summary, we have identified three peptide cocktails for prioritization in larger trials to discriminate between M. bovis infection and BCG vaccination.Despite the current “test and slaughter” control policy, the incidence of bovine tuberculosis (BTB), a zoonotic infection in cattle caused by Mycobacterium bovis, has been steadily rising in Great Britain over the last 20 years (10). Thus, the British government has acknowledged the urgent need for an effective cattle vaccine. To date, the only available vaccine for bovine tuberculosis is M. bovis bacillus Calmette-Guérin (BCG), an attenuated strain of M. bovis which has shown various levels of efficacy in cattle (4, 6, 23). More recent studies have shown that by utilizing a heterologous prime-boost approach, the efficacy of BCG vaccination can be significantly improved following boosting with DNA (17), protein (24), or viral (19-21) subunit vaccines. However, vaccination with BCG results in sensitization of animals to bovine tuberculin and compromises the single intradermal comparative tuberculin test (SICCT) currently used for diagnosis of bovine TB infection. Thus, to ensure the continuation of testing and slaughter-based control strategies, it is imperative that a complementary diagnostic test capable of discriminating between infected and uninfected vaccinated animals (DIVA) is developed in parallel with vaccine initiatives.Different but complementary approaches have been used to identify antigens showing potential as a DIVA reagent. Genetic analysis has revealed regions of difference (RDs) deleted during the evolution of BCG (3, 5, 11), and several of the antigens (including ESAT-6 [Rv3875] and CFP-10 [Rv3874]) located in these RDs have been shown to possess outstanding diagnostic potential for the detection of mycobacterial infection in both cattle and humans (1, 2, 7, 13, 22). Furthermore, some of these antigens (e.g., Rv3875, Rv3874, Rv1986, Rv3872, and Rv3878) are differentially recognized by M. bovis-infected cattle compared to BCG-vaccinated animals (8, 22). Alternatively, microarray analysis that quantified the level of M. bovis gene expression revealed the “abundant invariome,” a population of gene products that were consistently expressed at high levels under a variety of different culture conditions (16). One member of the abundant invariome, Rv3615c, stimulated gamma interferon (IFN-γ) responses in M. bovis-infected cattle but not in BCG-vaccinated animals (15). In addition, Rv3615c induced responses in a proportion of animals that failed to recognize an ESAT-6-CFP-10 peptide cocktail, suggesting that target antigens identified through different approaches have the potential to complement each other in the detection of M. bovis-infected cattle.In tuberculosis research, it has long been held that active secretion of antigenic proteins by mycobacteria induces strong cellular immune responses in the host. Indeed, we have often observed that, in general, secreted proteins are among the most frequently recognized antigens in M. bovis-infected cattle. Thus, the objective of this present study was to screen a panel of potential M. bovis secreted antigens in order to identify immunogenic targets and to formulate peptide cocktails that distinguish between M. bovis-infected and BCG-vaccinated animals in blood-based screening assays. 相似文献
15.
Shelley G. Rhodes Lucy C. McKinna Sabine Steinbach Gilly S. Dean Bernardo Villarreal-Ramos Adam O. Whelan C. Pirson Gareth J. Jones Derek Clifford H. Martin Vordermeier 《Clinical and Vaccine Immunology : CVI》2014,21(1):39-45
We describe here the application of a novel bovine interleukin-2 (IL-2) enzyme-linked immunosorbent assay (ELISA) for the measurement of antigen-specific IL-2 in cattle naturally infected with Mycobacterium bovis and in cattle vaccinated with Mycobacterium bovis BCG and then experimentally challenged with pathogenic M. bovis. Supernatants from whole-blood cultures stimulated with mycobacterial antigen (bovine purified protein derivative [PPDB] or the peptide cocktail ESAT6-CFP10) were assessed using a sandwich ELISA consisting of a new recombinant monoclonal fragment capture antibody and a commercially available polyclonal anti-bovine-IL-2. The production of IL-2 was compared to the production of gamma interferon (IFN-γ) in the same antigen-stimulated whole-blood supernatants. The data show that cattle infected with M. bovis produced quantifiable levels of antigen-specific IL-2, while IL-2 levels in cattle vaccinated with M. bovis BCG did not. Furthermore, cattle vaccinated with M. bovis BCG and then challenged with pathogenic M. bovis displayed a more rapid induction of IL-2 but ultimately had lower levels of infection-induced IL-2 than did unvaccinated challenge control cattle. These data suggest that IL-2 responses are not detectable post-BCG vaccination and that these responses may require infection with virulent M. bovis to develop. This may be useful to differentiate infected cattle from uninfected or BCG-vaccinated cattle, although the overall sensitivity is relatively low, particularly in single intradermal comparative cervical tuberculin (SICCT)-negative infected animals. Furthermore, the strength of the IL-2 response may correlate with pathology, which poses interesting questions on the immunobiology of bovine tuberculosis in contrast to human tuberculosis, which is discussed. 相似文献
16.
Helicobacter hepaticus Triggers Colitis in Specific-Pathogen-Free Interleukin-10 (IL-10)-Deficient Mice through an IL-12- and Gamma Interferon-Dependent Mechanism 总被引:10,自引:0,他引:10
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Marika C. Kullberg Jerrold M. Ward Peter L. Gorelick Patricia Caspar Sara Hieny Allen Cheever Dragana Jankovic Alan Sher 《Infection and immunity》1998,66(11):5157-5166
Mice rendered deficient in interleukin-10 (IL-10) by gene targeting (IL-10−/− mice) develop chronic enterocolitis resembling human inflammatory bowel disease (IBD) when maintained in conventional animal facilities. However, they display a minimal and delayed intestinal inflammatory response when reared under specific-pathogen-free (SPF) conditions, suggesting the involvement of a microbial component in pathogenesis. We show here that experimental infection with a single bacterial agent, Helicobacter hepaticus, induces chronic colitis in SPF-reared IL-10−/− mice and that the disease is accompanied by a type 1 cytokine response (gamma interferon [IFN-γ], tumor necrosis factor alpha, and nitric oxide) detected by restimulation of spleen and mesenteric lymph node cells with a soluble H. hepaticus antigen (Ag) preparation. In contrast, wild-type (WT) animals infected with the same bacteria did not develop disease and produced IL-10 as the dominant cytokine in response to Helicobacter Ag. Strong H. hepaticus-reactive antibody responses as measured by Ag-specific total immunoglobulin G (IgG), IgG1, IgG2a, IgG2b, IgG3, and IgA were observed in both WT and IL-10−/− mice. In vivo neutralization of IFN-γ or IL-12 resulted in a significant reduction of intestinal inflammation in H. hepaticus-infected IL-10−/− mice, suggesting an important role for these cytokines in the development of colitis in the model. Taken together, these microbial reconstitution experiments formally establish that a defined bacterial agent can serve as the immunological target in the development of large bowel inflammation in IL-10−/− mice and argue that in nonimmunocompromised hosts IL-10 stimulated in response to intestinal flora is important in preventing IBD. 相似文献
17.
Use of Antibodies in Lymphocyte Secretions for Detection of Subclinical Tuberculosis Infection in Asymptomatic Contacts
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rubhana Raqib S. M. Mostafa Kamal M. Jubayer Rahman Zeaur Rahim Sayera Banu Pradip K. Bardhan Fahima Chowdhury Gul Ara K. Zaman Robert F. Breiman Jan Andersson David A. Sack 《Clinical and Vaccine Immunology : CVI》2004,11(6):1022-1027
We have previously demonstrated that Mycobacterium bovis BCG-specific immunoglobulin G antibodies in lymphocyte secretions (ALS) can be employed as a marker for active tuberculosis (TB). We aimed to determine whether the ALS method allows detection of subclinical TB infection in asymptomatic individuals. A prospective study of family contacts (FCs) of patients with active TB and healthy controls was performed. Thirteen of 42 FCs had high ALS responses, including 6 FCs who subsequently developed active TB. No correlation was observed between the tuberculin skin test and the ALS responses in the FCs (r = 0.1, P = 0.23). Among patients with active TB, BCG-specific ALS responses steadily declined from the time of diagnosis through 6 months following antimycobacterial chemotherapy (P = 0.001). The ALS assay enabled detection of infection in exposed symptom-free contacts, who are at greater risk for developing active TB. The method may also allow discrimination between effective treatment of active infection and suboptimal response to therapy. 相似文献
18.
Shihoko Komine-Aizawa Toshio Yamazaki Tsuyoshi Yamazaki Shin-ichiro Hattori Yuji Miyamoto Naoki Yamamoto Shinji Haga Masahiko Sugitani Mitsuo Honda Satoshi Hayakawa Saburo Yamamoto 《Clinical and Vaccine Immunology : CVI》2010,17(10):1500-1506
Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only tuberculosis (TB) vaccine currently available, but its efficacy against adult pulmonary TB remains controversial. BCG induces specific immune responses to mycobacterial antigens and may elicit protective immunity against TB. TB remains a major public health problem, especially among the elderly, yet the efficacy of BCG in the elderly is unknown. We investigated the ability of BCG vaccination to prevent TB in young (6-week-old), middle-aged (18-month-old), and old (60-month-old) guinea pigs. BCG-Tokyo vaccination reduced the growth of Mycobacterium tuberculosis H37Rv in all three groups. By use of an enzyme-linked immunospot (ELISPOT) assay, antigen-specific gamma interferon (IFN-γ)-producing cells were detected in the 60-month-old guinea pigs after a booster vaccination with BCG-Tokyo. Our findings suggest that BCG-Tokyo has a protective effect against tuberculosis infection regardless of age.Tuberculosis (TB) remains a major public health problem, especially among elderly people. Patients ≥60 years of age account for ≥50% of new cases in Japan (29). The increasing susceptibility of the elderly to Mycobacterium tuberculosis is generally thought to be associated with age-related changes in immune system function, especially losses or delays in antigen-specific CD4+ T-cell function (14). Compromised antigen-specific CD4+ T-cell responses may contribute to increased susceptibility to M. tuberculosis infection in mice (27).Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only TB vaccine currently available. BCG has been used for more than 80 years (41), and vaccination with BCG is the standard for TB prevention in most countries. BCG induces specific immune responses to mycobacterial antigens and may elicit protective immunity against tuberculosis. BCG provides efficient protection against severe and disseminated TB, such as tuberculosis meningitis and miliary tuberculosis, in children (33, 34, 40). Although the long-term efficacy of BCG has been documented (3, 6), with several reports indicating efficient protection against disseminated TB in newborns and children, it appears to have less efficacy against adult pulmonary TB (2). In fact, its efficacy against pulmonary TB in both adults and the elderly is controversial, as is the efficacy of revaccination (5).In the present study, we examined the efficacy of BCG against TB at different ages in a common guinea pig model (15, 25, 30). We used three age-segregated groups—young (6 weeks old), middle-aged (18 months old), and old (60 months old)—and we measured the number of antigen-specific gamma interferon (IFN-γ)-producing cells as an indicator of the efficacy of the vaccine against TB. 相似文献
19.
Mardi C. Boer Corine Prins Krista E. van Meijgaarden Jaap T. van Dissel Tom H. M. Ottenhoff Simone A. Joosten 《Clinical and Vaccine Immunology : CVI》2015,22(7):778-788
Mycobacterium bovis bacillus Calmette-Guérin (BCG), the only currently available vaccine against tuberculosis, induces variable protection in adults. Immune correlates of protection are lacking, and analyses on cytokine-producing T cell subsets in protected versus unprotected cohorts have yielded inconsistent results. We studied the primary T cell response, both proinflammatory and regulatory T cell responses, induced by BCG vaccination in adults. Twelve healthy adult volunteers who were tuberculin skin test (TST) negative, QuantiFERON test (QFT) negative, and BCG naive were vaccinated with BCG and followed up prospectively. BCG vaccination induced an unexpectedly dichotomous immune response in this small, BCG-naive, young-adult cohort: BCG vaccination induced either gamma interferon-positive (IFN-γ+) interleukin 2-positive (IL-2+) tumor necrosis factor α-positive (TNF-α+) polyfunctional CD4+ T cells concurrent with CD4+ IL-17A+ and CD8+ IFN-γ+ T cells or, in contrast, virtually absent cytokine responses with induction of CD8+ regulatory T cells. Significant induction of polyfunctional CD4+ IFN-γ+ IL-2+ TNF-α+ T cells and IFN-γ production by peripheral blood mononuclear cells (PBMCs) was confined to individuals with strong immunization-induced local skin inflammation and increased serum C-reactive protein (CRP). Conversely, in individuals with mild inflammation, regulatory-like CD8+ T cells were uniquely induced. Thus, BCG vaccination either induced a broad proinflammatory T cell response with local inflammatory reactogenicity or, in contrast, a predominant CD8+ regulatory T cell response with mild local inflammation, poor cytokine induction, and absent polyfunctional CD4+ T cells. Further detailed fine mapping of the heterogeneous host response to BCG vaccination using classical and nonclassical immune markers will enhance our understanding of the mechanisms and determinants that underlie the induction of apparently opposite immune responses and how these impact the ability of BCG to induce protective immunity to TB. 相似文献
20.
Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Seon-Hee Cheon Beate Kampmann Amy G. Hise Manijeh Phillips Ho-Yeon Song Katherine Landen Qing Li Rhonda Larkin Jerrold J. Ellner Richard F. Silver Daniel F. Hoft Robert S. Wallis 《Clinical and Vaccine Immunology : CVI》2002,9(4):901-907
The development of new tuberculosis (TB) vaccines will require the identification of correlates of human protection. This study examined the balance between immunity and virulence in a whole blood infection model in which intracellular mycobacterial survival was measured using BACTEC. In the blood of tuberculin-negative donors, counts of Mycobacterium tuberculosis H37Ra organisms fell by 0.14 log10 CFU during 96 h of whole blood culture, whereas counts of Mycobacterium bovis BCG, M. tuberculosis H37Rv, and a clinical TB isolate's organisms increased by 0.13, 0.43, and 1.04 log10 CFU, respectively (P < 0.001), consistent with their relative virulence. Inhibition of tumor necrosis factor alpha by the addition of methylprednisolone or pentoxifylline or removal of CD4+ or CD8+ T cells by magnetic beads had deleterious effects on immune control of intracellular growth only in the blood of tuberculin-positive donors. Repeated vaccination of eight tuberculin-negative volunteers with M. bovis BCG resulted in a 0.3 log (50%) reduction in BCG CFU counts in the model compared to baseline values (P < 0.05). Three of the volunteers responded only after the second vaccination. These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted. 相似文献